L-Carnitine improves gastrointestinal disorders and altered the intestinal microbiota in hemodialysis patients

Junichiro Irie, Yoshihiko Kanno, Rieko Kikuchi, Tadashi Yoshida, Seizo Murai, Miwako Watanabe, Hiroshi Itoh, Matsuhiko Hayashi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Patients receiving hemodialysis also manifest gastrointestinal symptoms, such as constipation, caused by restriction of water intake and the loss of body water balance. Because dietary carnitine deficiency is considered to cause smooth muscle dysmotility of the gastrointestinal tract similarly to that in skeletal muscles, carnitine deficiency in hemodialysis patients may be one cause of gastrointestinal discomfort and dysfunctions. We performed a multicenter nonrandomized single-arm prospective clinical trial. Fifteen Japanese patients receiving hemodialysis were administered L-carnitine tablets (900 mg) for 3 months, and clinical and biochemical analyses were performed before and after treatment. The serum total carnitine level was increased significantly by supplementation with L-carnitine for 3 months (from 40.9 ± 2.6 μmol/l to 172.3 ± 19.0 μmol/l, p < 0.05). The myasthenia score was decreased significantly by the supplementation (from 1.3 ± 0.3 to 0.8 ± 0.2, p < 0.05). The frequency of passing stool tended to increase with the treatment for 3 months (from 4.2 ± 0.5 times/week to 4.8 ± 0.5 times/week). A phyla-level analysis of the microbiota showed that the composition of the individual microbiota was not different between before and after supplementation. A genus-level analysis, however, revealed that the relative abundance of genus Clostridium subcluster 4 was significantly decreased by the supplementation (from 7.7 ± 1.9% to 4.7 ± 1.3%, p < 0.05). Oral supplementation of L-carnitine to the patients receiving hemodialysis improved not only their muscle discomfort but also their gastrointestinal disorders and microbiota, although its effect on the prognosis of hemodialysis patients should be further investigated.

Original languageEnglish
Pages (from-to)11-16
Number of pages6
JournalBioscience of Microbiota, Food and Health
Volume36
Issue number1
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

hemodialysis
Carnitine
carnitine
digestive system diseases
intestinal microorganisms
Renal Dialysis
Microbiota
constipation
Clostridium
Body Water
Constipation
prospective studies
water balance
smooth muscle
Tablets
signs and symptoms (animals and humans)
Drinking
prognosis
body water
gastrointestinal system

Keywords

  • Carnitine
  • Clostridium
  • Constipation
  • Microbiota

ASJC Scopus subject areas

  • Food Science
  • Microbiology
  • Immunology
  • Applied Microbiology and Biotechnology
  • Gastroenterology

Cite this

L-Carnitine improves gastrointestinal disorders and altered the intestinal microbiota in hemodialysis patients. / Irie, Junichiro; Kanno, Yoshihiko; Kikuchi, Rieko; Yoshida, Tadashi; Murai, Seizo; Watanabe, Miwako; Itoh, Hiroshi; Hayashi, Matsuhiko.

In: Bioscience of Microbiota, Food and Health, Vol. 36, No. 1, 01.01.2017, p. 11-16.

Research output: Contribution to journalArticle

Irie, Junichiro ; Kanno, Yoshihiko ; Kikuchi, Rieko ; Yoshida, Tadashi ; Murai, Seizo ; Watanabe, Miwako ; Itoh, Hiroshi ; Hayashi, Matsuhiko. / L-Carnitine improves gastrointestinal disorders and altered the intestinal microbiota in hemodialysis patients. In: Bioscience of Microbiota, Food and Health. 2017 ; Vol. 36, No. 1. pp. 11-16.
@article{2e83b0b7203e466c85668c6ab3f43a73,
title = "L-Carnitine improves gastrointestinal disorders and altered the intestinal microbiota in hemodialysis patients",
abstract = "Patients receiving hemodialysis also manifest gastrointestinal symptoms, such as constipation, caused by restriction of water intake and the loss of body water balance. Because dietary carnitine deficiency is considered to cause smooth muscle dysmotility of the gastrointestinal tract similarly to that in skeletal muscles, carnitine deficiency in hemodialysis patients may be one cause of gastrointestinal discomfort and dysfunctions. We performed a multicenter nonrandomized single-arm prospective clinical trial. Fifteen Japanese patients receiving hemodialysis were administered L-carnitine tablets (900 mg) for 3 months, and clinical and biochemical analyses were performed before and after treatment. The serum total carnitine level was increased significantly by supplementation with L-carnitine for 3 months (from 40.9 ± 2.6 μmol/l to 172.3 ± 19.0 μmol/l, p < 0.05). The myasthenia score was decreased significantly by the supplementation (from 1.3 ± 0.3 to 0.8 ± 0.2, p < 0.05). The frequency of passing stool tended to increase with the treatment for 3 months (from 4.2 ± 0.5 times/week to 4.8 ± 0.5 times/week). A phyla-level analysis of the microbiota showed that the composition of the individual microbiota was not different between before and after supplementation. A genus-level analysis, however, revealed that the relative abundance of genus Clostridium subcluster 4 was significantly decreased by the supplementation (from 7.7 ± 1.9{\%} to 4.7 ± 1.3{\%}, p < 0.05). Oral supplementation of L-carnitine to the patients receiving hemodialysis improved not only their muscle discomfort but also their gastrointestinal disorders and microbiota, although its effect on the prognosis of hemodialysis patients should be further investigated.",
keywords = "Carnitine, Clostridium, Constipation, Microbiota",
author = "Junichiro Irie and Yoshihiko Kanno and Rieko Kikuchi and Tadashi Yoshida and Seizo Murai and Miwako Watanabe and Hiroshi Itoh and Matsuhiko Hayashi",
year = "2017",
month = "1",
day = "1",
doi = "10.12938/bmfh.16-009",
language = "English",
volume = "36",
pages = "11--16",
journal = "Bioscience of Microbiota, Food and Health",
issn = "2186-6953",
publisher = "BMFH Press",
number = "1",

}

TY - JOUR

T1 - L-Carnitine improves gastrointestinal disorders and altered the intestinal microbiota in hemodialysis patients

AU - Irie, Junichiro

AU - Kanno, Yoshihiko

AU - Kikuchi, Rieko

AU - Yoshida, Tadashi

AU - Murai, Seizo

AU - Watanabe, Miwako

AU - Itoh, Hiroshi

AU - Hayashi, Matsuhiko

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Patients receiving hemodialysis also manifest gastrointestinal symptoms, such as constipation, caused by restriction of water intake and the loss of body water balance. Because dietary carnitine deficiency is considered to cause smooth muscle dysmotility of the gastrointestinal tract similarly to that in skeletal muscles, carnitine deficiency in hemodialysis patients may be one cause of gastrointestinal discomfort and dysfunctions. We performed a multicenter nonrandomized single-arm prospective clinical trial. Fifteen Japanese patients receiving hemodialysis were administered L-carnitine tablets (900 mg) for 3 months, and clinical and biochemical analyses were performed before and after treatment. The serum total carnitine level was increased significantly by supplementation with L-carnitine for 3 months (from 40.9 ± 2.6 μmol/l to 172.3 ± 19.0 μmol/l, p < 0.05). The myasthenia score was decreased significantly by the supplementation (from 1.3 ± 0.3 to 0.8 ± 0.2, p < 0.05). The frequency of passing stool tended to increase with the treatment for 3 months (from 4.2 ± 0.5 times/week to 4.8 ± 0.5 times/week). A phyla-level analysis of the microbiota showed that the composition of the individual microbiota was not different between before and after supplementation. A genus-level analysis, however, revealed that the relative abundance of genus Clostridium subcluster 4 was significantly decreased by the supplementation (from 7.7 ± 1.9% to 4.7 ± 1.3%, p < 0.05). Oral supplementation of L-carnitine to the patients receiving hemodialysis improved not only their muscle discomfort but also their gastrointestinal disorders and microbiota, although its effect on the prognosis of hemodialysis patients should be further investigated.

AB - Patients receiving hemodialysis also manifest gastrointestinal symptoms, such as constipation, caused by restriction of water intake and the loss of body water balance. Because dietary carnitine deficiency is considered to cause smooth muscle dysmotility of the gastrointestinal tract similarly to that in skeletal muscles, carnitine deficiency in hemodialysis patients may be one cause of gastrointestinal discomfort and dysfunctions. We performed a multicenter nonrandomized single-arm prospective clinical trial. Fifteen Japanese patients receiving hemodialysis were administered L-carnitine tablets (900 mg) for 3 months, and clinical and biochemical analyses were performed before and after treatment. The serum total carnitine level was increased significantly by supplementation with L-carnitine for 3 months (from 40.9 ± 2.6 μmol/l to 172.3 ± 19.0 μmol/l, p < 0.05). The myasthenia score was decreased significantly by the supplementation (from 1.3 ± 0.3 to 0.8 ± 0.2, p < 0.05). The frequency of passing stool tended to increase with the treatment for 3 months (from 4.2 ± 0.5 times/week to 4.8 ± 0.5 times/week). A phyla-level analysis of the microbiota showed that the composition of the individual microbiota was not different between before and after supplementation. A genus-level analysis, however, revealed that the relative abundance of genus Clostridium subcluster 4 was significantly decreased by the supplementation (from 7.7 ± 1.9% to 4.7 ± 1.3%, p < 0.05). Oral supplementation of L-carnitine to the patients receiving hemodialysis improved not only their muscle discomfort but also their gastrointestinal disorders and microbiota, although its effect on the prognosis of hemodialysis patients should be further investigated.

KW - Carnitine

KW - Clostridium

KW - Constipation

KW - Microbiota

UR - http://www.scopus.com/inward/record.url?scp=85046971091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046971091&partnerID=8YFLogxK

U2 - 10.12938/bmfh.16-009

DO - 10.12938/bmfh.16-009

M3 - Article

AN - SCOPUS:85046971091

VL - 36

SP - 11

EP - 16

JO - Bioscience of Microbiota, Food and Health

JF - Bioscience of Microbiota, Food and Health

SN - 2186-6953

IS - 1

ER -